CLPT Stock Price, ClearPoint Neuro Inc Quote, Chart

Market Summary

6.20-0.20

Market Closed

-3.13%

CLPT Stock Price

View Fullscreen

CLPT RSI Chart

CLPT Valuation

Market Cap

170.0M

Price/Earnings (Trailing)

-8.24

Price/Sales (Trailing)

6.5

Price/Free Cashflow

-13.65

CLPT Price/Sales (Trailing)

CLPT Profitability

Operating Margin

57.10%

Return on Equity

-59.64%

Return on Assets

-38.45%

Free Cashflow Yield

-7.33%

CLPT Fundamentals

CLPT Revenue

Revenue (TTM)

26.2M

Rev. Growth (Yr)

40.6%

Rev. Growth (Qtr)

12.17%

CLPT Earnings

Earnings (TTM)

-20.6M

Earnings Growth (Yr)

26.08%

Earnings Growth (Qtr)

10.24%

Breaking Down CLPT Revenue

Last 7 days

5.8%

Last 30 days

12.1%

Last 90 days

-15.3%

Trailing 12 Months

-26.0%

How does CLPT drawdown profile look like?

CLPT Financial Health

Current Ratio

3.14

Debt/Equity

0.29

Debt/Cashflow

-1.19

CLPT Investor Care

Shares Dilution (1Y)

11.55%

Diluted EPS (TTM)

-0.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	26.2M	0	0	0
2023	21.0M	21.7M	22.3M	24.0M
2022	17.3M	19.1M	19.7M	20.6M
2021	13.7M	14.7M	15.7M	16.3M
2020	11.9M	11.7M	12.3M	12.8M
2019	8.2M	9.2M	10.3M	11.2M
2018	7.0M	6.7M	6.8M	7.4M
2017	6.4M	7.2M	7.3M	7.4M
2016	3.7M	4.4M	5.1M	5.7M
2015	2.8M	1.7M	2.3M	3.0M
2014	3.5M	4.1M	3.8M	2.6M
2013	5.3M	4.8M	4.6M	3.9M
2012	4.0M	4.4M	4.4M	5.1M
2011	3.0M	3.2M	3.5M	3.8M
2010	0	0	0	2.7M
2009	0	0	0	2.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of ClearPoint Neuro Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	richards timothy t.	acquired	11,152	6.8	1,640	-
Apr 01, 2024	liau linda m.	acquired	2,964	6.8	436	-
Apr 01, 2024	girin pascal e r	acquired	7,180	6.8	1,056	-
Apr 01, 2024	fletcher r john	acquired	5,780	6.8	850	-
Mar 06, 2024	sabra mazin	acquired	-	-	6,913	chief operating officer
Mar 06, 2024	stigall l. jeremy	sold (taxes)	-19,843	6.24	-3,180	chief business officer
Mar 06, 2024	d'alessandro danilo	sold (taxes)	-29,440	6.24	-4,718	chief financial officer
Mar 06, 2024	d'alessandro danilo	acquired	-	-	9,383	chief financial officer
Mar 06, 2024	sabra mazin	sold (taxes)	-21,609	6.24	-3,463	chief operating officer
Mar 06, 2024	burnett joseph michael	acquired	-	-	23,704	ceo and president

Which funds bought or sold CLPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-38.93	-77,316	121,760	-%
May 16, 2024	AWM Investment Company, Inc.	new	-	893,731	893,731	0.12%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.91	-9,945	15,674	-%
May 15, 2024	D. E. Shaw & Co., Inc.	new	-	282,982	282,982	-%
May 15, 2024	Sentinus, LLC	new	-	101,796	101,796	0.04%
May 15, 2024	POM Investment Strategies, LLC	unchanged	-	-	102	-%
May 15, 2024	Federation des caisses Desjardins du Quebec	new	-	81,600	81,600	-%
May 15, 2024	BARCLAYS PLC	reduced	-48.74	-104,000	110,000	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-65.42	-158,641	84,061	-%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	7.86	13,000	170,000	-%

Are Funds Buying or Selling CLPT?

Are funds buying CLPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CLPT

No. of Funds

Unveiling ClearPoint Neuro Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.32%	1,308,694	SC 13G
Feb 06, 2024	bigger capital, llc	3.5%	868,042	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	1,470,056	SC 13G
Jun 15, 2023	ptc therapeutics, inc.	9.76%	2,561,245	SC 13D/A
Feb 09, 2023	bigger capital fund l p	3.0%	746,994	SC 13G/A
Jan 26, 2022	bigger capital fund l p	2.8%	655,690	SC 13G/A
Jun 09, 2021	bigger capital fund l p	2.8%	575,484	SC 13G
Mar 02, 2021	ptc therapeutics, inc.	14.00%	2,961,245	SC 13D/A
Feb 11, 2021	satterfield thomas a jr	4.0%	720,000	SC 13G/A
Feb 13, 2020	satterfield thomas a jr	7.8%	1,225,000	SC 13G/A

Recent SEC filings of ClearPoint Neuro Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 16, 2024	S-8	Employee Benefits Plan
May 16, 2024	8-K	Current Report
May 15, 2024	4	Insider Trading

Peers (Alternatives to ClearPoint Neuro Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

ClearPoint Neuro Inc News

Latest updates

ClearPoint Neuro Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	12.2%	7,639	6,810	5,762	5,950	5,433	5,174	5,146	5,200	5,031	4,282	4,574	3,413	4,030	3,716	3,519	2,478	3,116	3,211	2,927	2,606	2,473
Cost Of Revenue	11.3%	3,114	2,797	2,489	2,824	2,231	1,808	1,467	1,945	1,800	1,093	1,533	1,139	1,416	1,073	903	802	932	1,042	983	1,030	886
Gross Profit	12.8%	4,525	4,013	3,273	3,126	3,202	3,366	3,679	3,255	3,231	3,189	3,041	2,274	2,614	-	2,616	1,676	-	-	-	-	-
S&GA Expenses	4.4%	2,841	2,720	2,900	3,178	2,958	2,376	2,398	2,661	2,176	1,931	2,436	1,982	1,657	1,528	1,252	1,214	1,276	1,312	1,030	1,028	933
R&D Expenses	-1.0%	2,625	2,652	2,429	3,605	3,023	2,928	2,654	2,411	2,901	3,041	2,601	2,109	1,563	1,913	1,143	812	818	766	762	698	585
Interest Expenses	22.0%	111	91.00	100	81.00	114	84.00	32.00	-91.00	-106	1,211	-238	240	332	204	201	197	842	229	213	259	254
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	10.2%	-4,146	-4,619	-4,809	-7,052	-5,609	-4,385	-3,788	-4,303	-3,959	-4,149	-3,980	-3,743	-2,538	-1,582	-1,484	-1,661	-2,055	-1,645	-1,122	-1,550	-1,220
Net Income Margin	14.5%	-0.79*	-0.92*	-0.98*	-0.96*	-0.86*	-0.80*	-0.82*	-0.86*	-0.92*	-0.88*	-0.75*	-0.64*	-	-	-	-	-	-	-	-	-
Free Cashflow	-236.5%	-3,840	-1,141	-2,080	-5,398	-5,818	-3,104	-3,921	-5,057	-4,338	-3,590	-3,421	-3,683	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	25.7%	54.00	43.00	44.00	48.00	50.00	55.00	58.00	60.00	62.00	66.00	69.00	72.00	74.00	30.00	22.00	23.00	24.00	12.00	13.00	13.00	8.00
Current Assets	31.5%	48.00	36.00	37.00	41.00	46.00	51.00	54.00	57.00	58.00	62.00	65.00	69.00	70.00	25.00	20.00	21.00	22.00	10.00	12.00	12.00	6.00
Cash Equivalents	52.8%	35.00	23.00	24.00	27.00	22.00	28.00	19.00	24.00	50.00	54.00	58.00	62.00	65.00	20.00	15.00	16.00	17.00	6.00	6.00	7.00	2.00
Inventory	0.6%	8.00	8.00	9.00	9.00	10.00	9.00	8.00	7.00	6.00	5.00	4.00	4.00	3.00	3.00	4.00	4.00	4.00	3.00	3.00	3.00	2.00
Net PPE	-3.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-11.3%	19.00	21.00	20.00	20.00	18.00	19.00	18.00	17.00	16.00	17.00	25.00	24.00	30.00	27.00	22.00	22.00	21.00	7.00	7.00	6.00	7.00
Current Liabilities	104.0%	15.00	7.00	6.00	6.00	6.00	7.00	6.00	5.00	4.00	5.00	5.00	4.00	3.00	3.00	4.00	4.00	4.00	4.00	4.00	3.00	2.00
Long Term Debt	0.2%	10.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-	1.00	1.00	-	-	-	-	-
Shareholder's Equity	63.3%	35.00	21.00	24.00	27.00	33.00	37.00	40.00	43.00	46.00	49.00	44.00	48.00	44.00	2.00	0.00	1.00	3.00	5.00	6.00	7.00	0.00
Retained Earnings	-2.7%	-176	-172	-167	-163	-156	-150	-145	-142	-137	-133	-130	-126	-122	-119	-117	-116	-114	-112	-111	-109	-108
Additional Paid-In Capital	9.1%	211	193	192	190	188	187	186	185	183	182	174	174	166	122	118	118	117	117	117	117	109
Shares Outstanding	11.2%	27.00	25.00	25.00	25.00	25.00	25.00	24.00	24.00	24.00	24.00	21.00	22.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	155	-	-	-	272	-	-	-	361	-	-	-	43.00	-	-	-	43.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-242.9%	-3,840	-1,120	-1,845	-5,075	-5,680	-3,065	-3,852	-4,981	-4,269	-3,552	-3,296	-3,718	-2,131	-2,401	-1,367	-1,708	-2,331	-466	-964	-810	-609
Share Based Compensation	-2.5%	1,504	1,543	1,584	1,645	1,307	1,172	1,175	880	899	925	586	247	320	328	293	241	228	223	219	204	153
Cashflow From Investing	100.0%	-	-188	-235	9,510	-138	11,746	-631	-21,666	-185	-38.00	-125	35.00	-40.00	-41.00	-	-	-441	190*	-10.19	-	-
Cashflow From Financing	10256.8%	16,053	155	-91.00	237	-5.00	222	-329	513	3.00	48.00	-452	349	46,930	7,876	-	764	14,052	-72.93	-252	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CLPT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 7,639	$ 5,433
Cost of revenue	3,114	2,231
Gross profit	4,525	3,202
Research and development costs	2,625	3,023
Sales and marketing expenses	3,290	2,933
General and administrative expenses	2,841	2,958
Operating loss	(4,231)	(5,712)
Other expense:
Other expense, net	(26)	(11)
Interest income, net	111	114
Net loss	$ (4,146)	$ (5,609)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.16)	$ (0.23)
Diluted (in dollars per share)	$ (0.16)	$ (0.23)
Weighted average shares used in computing net loss per share:
Basic (in shares)	25,452,096	24,583,163
Diluted (in shares)	25,452,096	24,583,163
Product revenue
Revenue:
Total revenue	$ 3,635	$ 2,630
Service and other revenue
Revenue:
Total revenue	$ 4,004	$ 2,803

CLPT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,353	$ 23,140
Accounts receivable, net	2,511	3,211
Inventory, net	7,960	7,911
Prepaid expenses and other current assets	1,746	1,910
Total current assets	47,570	36,172
Property and equipment, net	1,347	1,389
Operating lease, right-of-use assets	3,447	3,564
Software license inventory	237	386
Licensing rights	887	1,041
Other assets	149	109
Total assets	53,637	42,661
Current liabilities:
Accounts payable	844	393
Accrued compensation	1,634	2,947
Other accrued liabilities	986	1,053
Operating lease liabilities, current portion	497	424
Deferred product and service revenue, current portion	1,232	2,613
2020 senior secured convertible note payable, net	9,964	0
Total current liabilities	15,157	7,430
Operating lease liabilities, net of current portion	3,438	3,568
Deferred product and service revenue, net of current portion	458	541
2020 senior secured convertible note payable, net	0	9,949
Total liabilities	19,053	21,488
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value; 90,000,000 shares authorized at March 31, 2024 and December 31, 2023; 27,416,345 shares issued and outstanding at March 31, 2024; and 24,652,729 issued and outstanding at December 31, 2023	274	247
Additional paid-in capital	210,912	193,382
Accumulated deficit	(176,602)	(172,456)
Total stockholders’ equity	34,584	21,173
Total liabilities and stockholders’ equity	$ 53,637	$ 42,661

About ClearPoint Neuro Inc

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain. It has license and collaboration agreements with Clinical Laserthermia Systems AB, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

CEO	Mr. Joseph Michael Burnett
WEBSITE	clearpointneuro.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	108

ClearPoint Neuro Inc Frequently Asked Questions

What is the ticker symbol for ClearPoint Neuro Inc? What does CLPT stand for in stocks?

CLPT is the stock ticker symbol of ClearPoint Neuro Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ClearPoint Neuro Inc (CLPT)?

As of Fri May 17 2024, market cap of ClearPoint Neuro Inc is 170.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CLPT stock?

You can check CLPT's fair value in chart for subscribers.

What is the fair value of CLPT stock?

You can check CLPT's fair value in chart for subscribers. The fair value of ClearPoint Neuro Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ClearPoint Neuro Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CLPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ClearPoint Neuro Inc a good stock to buy?

The fair value guage provides a quick view whether CLPT is over valued or under valued. Whether ClearPoint Neuro Inc is cheap or expensive depends on the assumptions which impact ClearPoint Neuro Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CLPT.

What is ClearPoint Neuro Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CLPT's PE ratio (Price to Earnings) is -8.24 and Price to Sales (PS) ratio is 6.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CLPT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ClearPoint Neuro Inc's stock?

In the past 10 years, ClearPoint Neuro Inc has provided 0.179 (multiply by 100 for percentage) rate of return.